Showing 25–35 of 35 results

Promacta / Revolade 50 mg Alternative – Elopag (Eltrombopag) 50 mg Tablet | Everest Pharmaceuticals

Elopag 50 mg (Eltrombopag) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Promacta / Revolade (Novartis). It belongs to the thrombopoietin receptor agonist class and is used in selected immune thrombocytopenia and aplastic anemia settings.

Active ingredient: Eltrombopag
Strength: 50 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh

Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.

Retevmo / Retsevmo 40 mg Alternative – Selcaxen (Selpercatinib) 40 mg Capsule | Everest Pharmaceuticals

Selcaxen 40 mg (Selpercatinib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Retevmo / Retsevmo (Eli Lilly). It belongs to the RET inhibitor class and is used in selected RET-altered lung or thyroid cancers.

Active ingredient: Selpercatinib
Strength: 40 mg
Form: Capsule
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh

Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.

Tabrecta 200 mg Alternative – Capmaxen (Capmatinib) 200 mg Tablet | Everest Pharmaceuticals

Capmaxen 200 mg (Capmatinib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Tabrecta (Novartis). It belongs to the MET inhibitor class and is used in selected MET exon 14 skipping non-small cell lung cancer.

Active ingredient: Capmatinib
Strength: 200 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh

Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.

Tagrisso 80 mg Alternative – Osimert (Osimertinib) 80 mg Tablet | Everest Pharmaceuticals

Osimert 80 mg (Osimertinib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Tagrisso (AstraZeneca). It belongs to the EGFR tyrosine kinase inhibitor class and is used in selected EGFR-mutated non-small cell lung cancer.

Active ingredient: Osimertinib
Strength: 80 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh

Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.

Talzenna 1 mg Alternative – Talaparib (Talazoparib) 1 mg Capsule | Everest Pharmaceuticals

Talaparib 1 mg (Talazoparib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Talzenna (Pfizer). It belongs to the PARP inhibitor class and is used in selected genetically defined breast and prostate cancer treatment settings.

Active ingredient: Talazoparib
Strength: 1 mg
Form: Capsule
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh

Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.

Tukysa 150 mg Alternative – Tucaxen (Tucatinib) 150 mg Tablet | Everest Pharmaceuticals

Tucaxen 150 mg (Tucatinib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Tukysa (Seagen / Pfizer). It belongs to the HER2 tyrosine kinase inhibitor class and is used in selected HER2-positive breast cancer treatment combinations.

Active ingredient: Tucatinib
Strength: 150 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh

Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.

Votrient 200 mg Alternative – Pazorest (Pazopanib) 200 mg Tablet | Everest Pharmaceuticals

Pazorest 200 mg (Pazopanib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Votrient (Novartis). It belongs to the multitarget kinase inhibitor class and is used in selected advanced renal cell carcinoma and soft tissue sarcoma.

Active ingredient: Pazopanib
Strength: 200 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh

Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.

Xalkori 250 mg Alternative – Alkixen (Crizotinib) 250 mg Capsule | Everest Pharmaceuticals

Alkixen 250 mg (Crizotinib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Xalkori (Pfizer). It belongs to the ALK/ROS1 kinase inhibitor class and is used in selected ALK-positive or ROS1-positive non-small cell lung cancer.

Active ingredient: Crizotinib
Strength: 250 mg
Form: Capsule
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh

Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.

Xeloda 500 mg Alternative – Capixet (Capecitabine) 500 mg Tablet | Everest Pharmaceuticals

Capixet 500 mg (Capecitabine) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Xeloda (Roche). It belongs to the oral fluoropyrimidine chemotherapy class and is used in selected colorectal, breast and other cancer regimens.

Active ingredient: Capecitabine
Strength: 500 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh

Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.

Zejula 100 mg Alternative – Niranib (Niraparib) 100 mg Capsule | Everest Pharmaceuticals

Niranib 100 mg (Niraparib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Zejula (GSK). It belongs to the PARP inhibitor class and is used in selected ovarian cancer maintenance treatment settings.

Active ingredient: Niraparib
Strength: 100 mg
Form: Capsule
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh

Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.

Zytiga 250 mg Alternative – Abiraxen (Abiraterone acetate) 250 mg Tablet | Everest Pharmaceuticals

Abiraxen 250 mg (Abiraterone acetate) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Zytiga (Janssen). It belongs to the androgen biosynthesis inhibitor class and is used in selected advanced prostate cancer regimens with corticosteroid therapy.

Active ingredient: Abiraterone acetate
Strength: 250 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh

Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.